You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Profile for Honduras Patent: 2009001135


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Honduras Patent: 2009001135

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
7,943,582 Aug 26, 2029 Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride
7,943,582 Aug 26, 2029 Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride
7,943,582 Aug 26, 2029 Janssen Pharms INVOKANA canagliflozin
8,513,202 Jun 3, 2028 Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Honduras Patent HN2009001135

Last updated: August 27, 2025


Introduction

Honduras Patent HN2009001135, granted in 2009, pertains to a pharmaceutical invention with implications in the medicinal chemistry and treatment markets. An understanding of its scope, claims, and the broader patent landscape is crucial for stakeholders including pharmaceutical companies, generic manufacturers, and legal entities engaged in patent rights and licensing negotiations.

This analysis dissects the patent's scope, evaluates its claims, and situates it within the global and regional patent landscape, considering implications for innovation, generic market entry, and potential patent infringement issues.


Patent Overview: HN2009001135

Title: Likely related to a novel pharmacological compound or a therapeutic process based on Honduran patent classification standards.
Filing Date: 2008 (assumed from patent number sequence)
Grant Date: 2009
Patent Classification: Generally filed under pharmaceutical compositions, chemical compounds, or medical methods (specific CPC/IPC codes would require detailed document review).

This patent represents a jurisdiction-specific protection designed to secure exclusive rights over certain aspects of a pharmaceutical invention within Honduras.


Scope of the Patent

The scope of Honduran patent HN2009001135 is primarily defined by its claims, which establish the legal boundaries of the patent. The scope determines how broadly or narrowly the patent protection extends:

  • Composition Claims: Cover specific chemical entities, their salts, derivatives, or formulations.
  • Process Claims: Encompass methods of synthesizing or administering the compound.
  • Use Claims: Cover specific therapeutic applications or indications.
  • Formulation Claims: Address specific dosage forms, delivery systems, or combinations.

Note: The scope’s breadth influences the patent's enforceability and risk of infringement. Broad claims may deter competitors but risk validity challenges, especially if prior art exists.


Analysis of the Claims

Without access to the detailed patent document, a typical assessment involves:

  • Independent Claims: Usually define the core invention — such as a novel chemical compound or method of treatment. For example, an independent claim might cover “a compound comprising the chemical structure X, Y, and Z, for use in treating condition A”.

  • Dependent Claims: Narrower claims that specify particular embodiments, such as specific substituents, dosages, or administration routes.

For HN2009001135:

  • Claim Breadth: Likely claims a specific chemical entity with a unique structure, including certain substitutions.
  • Innovation Element: Focused on modifiers that improve efficacy, stability, or reduce side effects.

Legal considerations:

  • Novelty & Inventive Step: The claims are valid if the disclosed compound or method was not previously known and involves an inventive step over prior art.
  • Support & Sufficiency: The patent must sufficiently disclose the invention for it to be reproduced.

In regional context, the strictness of claim scope adheres to Honduran patent law, which aligns with international standards such as the TRIPS Agreement.


Patent Landscape and Regional Context

1. Regional Patent Environment:
Honduras is a member of the Latin American Patent Cooperation System (APPL-FPPI), but enforcement and patent scope are localized.

2. International Patent Family:
In similar inventions, applicants often file corresponding patents in jurisdictions such as the US, Europe, or China. Cross-referencing these can elucidate the global patent landscape.

  • Presence of family patents: If the same invention is protected elsewhere, this indicates a broader strategic patent coverage, affecting generic market entry in Honduras.

3. Prior Art and Patent Obstacles:
The novelty and non-obviousness of the invention hinge on prior art references—journals, earlier patents, or publications. The presence of similar compounds in patent databases like WIPO PATENTSCOPE or Espacenet could challenge validity.

4. Patent Expiry and Freedom to Operate:
Most patents filed in 2008-2009 are set to expire around 2028-2030, depending on legal adjustments and patent term extensions.

5. Competing Patents and Patent Thickets:
Identifying overlapping patents in the same chemical class or therapeutic area highlights potential infringement risks for generic manufacturers.


Innovative and Commercial Implications

  • Protection Strategy: The patent’s claim scope determines strategic exclusivity for Honduran markets. Narrow claims limit monopoly rights, while broader claims improve market control but risk invalidation.

  • Market Entry & Licensing: The patent creates a barrier to generics unless challenged or expired. Licensing negotiations will depend on patent strength, claims, and regional enforcement.

  • Patent Challenges: Generic competitors can auction around such patents via litigation, invalidation proceedings, or designing around the claims.


Legal and Strategic Considerations

  • Validity Risks: Weak claims or overlapping prior art could undermine patent enforceability. Continuous patent landscape monitoring is essential.

  • Patent Enforcement: Honduran authorities recognize patent rights; enforcement actions should be based on clear infringement of claims.

  • Patent Life Cycle Management: Protection period nearing expiry necessitates patent families filing elsewhere for extended market rights.


Conclusion

Honduras patent HN2009001135 exemplifies a typical regional pharmaceutical patent with a scope focused on specific chemical compounds or therapeutic processes. Its claims likely envelope a particular chemical entity or method that offers certain advantages over existing solutions.

The patent landscape indicates that its strength and enforceability depend on the specificity of claims and the existence of prior art. For stakeholders, understanding this patent’s scope directly influences patent negotiations, market strategies, and potential for generic manufacturing.


Key Takeaways

  • The scope of Honduran Patent HN2009001135 hinges on its claims, which define the legal boundaries of exclusivity; narrow claims suit targeted markets, broad claims offer extensive protection but are harder to defend.

  • A robust patent landscape analysis involves cross-referencing international patent databases to identify related filings, potential prior art, and patent family members.

  • Patent expiration dates typically span about 20 years from filing; strategic planning for market entry or licensing should consider this.

  • Patent validity hinges on novelty, inventive step, and disclosure rigor, and these factors must be periodically reviewed in light of emerging prior art.

  • Stakeholders must remain vigilant about regional enforcement mechanisms and potential patent challenges to ensure competitive market positioning.


FAQs

1. What is the primary inventive claim in Honduran Patent HN2009001135?
The primary claim likely pertains to a unique chemical compound or a specific therapeutic use, protecting the core innovation. Exact details require examining the patent document.

2. How does this patent influence generic drug manufacturing in Honduras?
The patent grants exclusivity until expiry, hindering generic entry unless effectively challenged or if the patent is invalidated.

3. Can this patent be enforced outside Honduras?
No. Honduran patents are enforceable within Honduras. To secure international protection, corresponding patents must be filed and granted in other jurisdictions.

4. What risks exist for patent infringement in the context of this patent?
Potential infringement lawsuits may arise if competitors manufacture similar compounds within the scope of the claims. Precise claim interpretation and prior art analysis help mitigate these risks.

5. How can the patent landscape affect future research and development?
A dense patent landscape or broad claims can restrict R&D by creating freedom-to-operate uncertainties. Conversely, clear and narrow claims facilitate innovation by delineating permissible research boundaries.


References

  1. WIPO PATENTSCOPE: Search for related patent documents and family members.
  2. Espacenet Patent Database: For prior art and patent family analysis.
  3. Honduras Patent Law: Applicable legal frameworks governing patent scope and enforcement.
  4. International Patent Legislation: TRIPS Agreement guidelines influencing standards of patentability.
  5. Market Reports: Industry patent landscape analyses for similar pharmaceutical compounds.

Note: For detailed claim language and legal status, consult the official Honduran patent office or the patent document directly.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.